Sara Isabel Pai, MD, PhD
ProfessorCards
About
Research
Publications
2025
Positioning and reversible suppression of CCR7+ dendritic cells in perivascular tumor niches shape cancer immunity
Zitti B, Duval F, Wirapati P, Hicham M, Xie Y, Oh J, Hoelzl J, Meiser P, Varrone M, Peterson H, Cianciaruso C, Bill R, Bayerl F, Bolli E, Goubet A, Kiss M, McDowell S, Cheng P, Celestini D, Terzic J, Zwahlen T, Alouche N, Zouggari N, Tarussio D, Tissot S, Nunes-Hasler P, Mino-Kenudson M, Lanuti M, Faquin W, Sadow P, Tille J, Intidhar Labidi-Galy S, Garris C, Hugues S, Petrova T, Ludewig B, Quezada S, Luther S, Mempel T, Ciriello G, Pai S, Michielin O, Böttcher J, Weissleder R, Pittet M. Positioning and reversible suppression of CCR7+ dendritic cells in perivascular tumor niches shape cancer immunity. Immunity 2025, 59: 161-176.e12. PMID: 41421339, DOI: 10.1016/j.immuni.2025.11.020.Peer-Reviewed Original ResearchThe science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
Coukos G, Donia M, Gastman B, Goff S, Gros A, Harari A, Hernandez S, Ito F, Maker A, Mullinax J, Murthy P, Pai S, Prabhakaran S, Restifo N, Silver N, Smith P, Turcotte S, Wagner P, Yang J, Lotze M. The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee. Journal For ImmunoTherapy Of Cancer 2025, 13: e013420. PMID: 41320228, DOI: 10.1136/jitc-2025-013420.Peer-Reviewed Original Research93 Spatial analysis of head and neck squamous cell cancer tumor microenvironment identifies predictors of pembrolizumab therapy
Oh J, Hoelzl J, Carlson J, Bill R, Peterson H, Faquin W, Pittet M, Pai S, Weissleder R. 93 Spatial analysis of head and neck squamous cell cancer tumor microenvironment identifies predictors of pembrolizumab therapy. 2025, a105-a105. DOI: 10.1136/jitc-2025-sitc2025.0093.Peer-Reviewed Original ResearchIn Response to A Clinical Consensus Statement on Pulmonary Recurrent Respiratory Papillomatosis
Kohli N, Pai S, Buckingham J, Carter Y, Saba N, Hung Y, Berkowitz D, Best S, Davis K, Morton C, Popler J, Pransky S, Piccione J, Smith D, Venkatramani R, Stiff M, Buchinsky F, Sidell D. In Response to A Clinical Consensus Statement on Pulmonary Recurrent Respiratory Papillomatosis. The Laryngoscope 2025 PMID: 41174897, DOI: 10.1002/lary.70233.Peer-Reviewed Original ResearchA Clinical Consensus Statement on Pulmonary Recurrent Respiratory Papillomatosis
Kohli N, Pai S, Buckingham J, Carter Y, Saba N, Hung Y, Berkowitz D, Best S, Davis K, Morton C, Popler J, Pransky S, Piccione J, Smith D, Venkatramani R, Stiff M, Buchinsky F, Sidell D. A Clinical Consensus Statement on Pulmonary Recurrent Respiratory Papillomatosis. The Laryngoscope 2025, 135: 4642-4650. PMID: 40747774, DOI: 10.1002/lary.32463.Peer-Reviewed Original ResearchRecurrent respiratory papillomatosisRespiratory papillomatosisRisk of malignant transformationMultidisciplinary expert consensusClinical consensus statementHPV typesSystemic therapySystemic treatmentThoracic surgeonsPediatric otolaryngologistsPulmonary lesionsMalignant transformationDisease progressionConsensus statementTreatment of orphan diseasesOrphan diseaseConsensus groupDiagnosisLevel V.Expert consensusPapillomatosisTreatmentMultidisciplinary teamDiseaseLiterature reviewSpatial analysis identifies DC niches as predictors of pembrolizumab therapy in head and neck squamous cell cancer
Oh J, Hoelzl J, Carlson J, Bill R, Peterson H, Faquin W, Pittet M, Pai S, Weissleder R. Spatial analysis identifies DC niches as predictors of pembrolizumab therapy in head and neck squamous cell cancer. Cell Reports Medicine 2025, 6: 102100. PMID: 40311615, PMCID: PMC12147904, DOI: 10.1016/j.xcrm.2025.102100.Peer-Reviewed Original ResearchEpigenetic therapy sensitizes anti–PD-1 refractory head and neck cancers to immunotherapy rechallenge
Qin T, Mattox A, Campbell J, Park J, Shin K, Li S, Sadow P, Faquin W, Micevic G, Daniels A, Haddad R, Garris C, Pittet M, Mempel T, ONeill A, Sartor M, Pai S. Epigenetic therapy sensitizes anti–PD-1 refractory head and neck cancers to immunotherapy rechallenge. Journal Of Clinical Investigation 2025, 135: e181671. PMID: 40091844, PMCID: PMC11910227, DOI: 10.1172/jci181671.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsAzacitidineB7-H1 AntigenEpigenesis, GeneticFemaleHead and Neck NeoplasmsHumansImmune Checkpoint InhibitorsImmunotherapyMaleMiddle AgedProgrammed Cell Death 1 ReceptorSquamous Cell Carcinoma of Head and NeckTumor MicroenvironmentConceptsHead and neck squamous cell carcinomaTumor microenvironmentProlonged OSOverall survivalIFN-gCD8+ T cell infiltrationCD4+ T regulatory cellsOn-treatment tumor biopsiesNeck squamous cell carcinomaSystemic host immune responseBackgroundImmune checkpoint blockadeMetastatic (R/MMedian overall survivalPD-L1 expressionT cell infiltrationLocal tumor microenvironmentT regulatory cellsSquamous cell carcinomaBiologically Effective DosePhase 1b clinical trialHost immune responseCheckpoint blockadeOS ratesPD-L1Tumor biopsiesQuantifying cell divisions along evolutionary lineages in cancer
Blohmer M, Cheek D, Hung W, Kessler M, Chatzidimitriou F, Wang J, Hung W, Lee I, Gorelick A, Wassenaar E, Yang C, Yeh Y, Ho H, Speiser D, Karsten M, Lanuti M, Pai S, Kranenburg O, Lennerz J, Chou T, Kloor M, Naxerova K. Quantifying cell divisions along evolutionary lineages in cancer. Nature Genetics 2025, 57: 706-717. PMID: 39905260, PMCID: PMC12765479, DOI: 10.1038/s41588-025-02078-5.Peer-Reviewed Original Research
2024
649 A phase 1 dose-escalation and expansion study of CUE-101 as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer
Chung C, Dimitrios Colevas A, Adkins D, Rodriguez C, Park J, Gibson M, Sukari A, Worden F, Johnson F, Saba N, Burtness B, Julian R, Bauman J, Jotte R, Seiwert T, Dunn L, Chaney M, Agensky L, Goel A, Levisetti M, Margossian S, Quayle S, Pai S. 649 A phase 1 dose-escalation and expansion study of CUE-101 as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer. 2024, a745-a745. DOI: 10.1136/jitc-2024-sitc2024.0649.Peer-Reviewed Original Research1540MO The patient voice: An analysis of real-world data using the recurrent respiratory papillomatosis foundation/CoRDS patient registry (RRPF/CoRDS)
Pai S, OChieng W, Hedlund N, Martino A, Chohan N, Pawlak M, Morais E, McClellan K. 1540MO The patient voice: An analysis of real-world data using the recurrent respiratory papillomatosis foundation/CoRDS patient registry (RRPF/CoRDS). Annals Of Oncology 2024, 35: s938. DOI: 10.1016/j.annonc.2024.08.1602.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Clinical Care
Overview
Sara Isabel Pai, MD, PhD, is a surgical oncologist who specializes in head and neck cancers associated with human papillomavirus (HPV), and in thyroid and parathyroid cancers/disorders. She uses a combination of surgical techniques and immunotherapy to improve patient outcomes.
“My personal goal for my career in medicine is to make a meaningful difference in people's lives. I strive to achieve this daily through patient care, as well as by impacting patients I may not meet personally through my research and the training of the next generation of surgeon-scientists.”
As a professor at Yale School of Medicine, Dr. Pai’s research focuses on cancer immunotherapy. She is particularly interested in understanding how HPV evades the immune system and aims to develop strategies to reactivate the immune response against HPV-related cancer cells. Her work has led to the Food and Drug Administration’s orphan drug designation for pembrolizumab in treating recurrent respiratory papillomatosis (RRP), a rare condition caused by HPV.
Dr. Pai has led several investigator-initiated and industry clinical trials and has over 120 publications in peer-reviewed journals. She serves as Senior Editor for Cancer Research. Dr. Pai completed her medical and doctoral degrees at Johns Hopkins University School of Medicine, focusing on cancer immunology and vaccines. She completed her residency in otolaryngology-head and neck surgery at Johns Hopkins Hospital.
Clinical Specialties
Fact Sheets
Head and Neck Cancer
Learn More on Yale Medicine
Board Certifications
Otolaryngology - Head & Neck Surgery
- Certification Organization
- AB of Otolaryngology - Head and Neck Surgery
- Latest Certification Date
- 2018
- Original Certification Date
- 2008
News
News
- January 07, 2025
Yale Surgeon-Scientist Secures FDA Orphan Drug Designation for Pembrolizumab in Rare Respiratory Disease
- October 17, 2024
Head and Neck Surgery at Smilow Cancer Hospital
- April 16, 2024
Yale-NY Regional Head & Neck Translational Research Symposium
- November 28, 2023
Department of Surgery Welcomes 16 Faculty & 9 Staff
Get In Touch
Contacts
Otolaryngology Surgery
330 Cedar Street, PO Box 208041
New Haven, CT 06520-8041
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.